| Year |
Citation |
Score |
| 2024 |
Basso V, Döbrössy MD, Thompson LH, Kirik D, Fuller HR, Gates MA. State of the Art in Sub-Phenotyping Midbrain Dopamine Neurons. Biology. 13. PMID 39336117 DOI: 10.3390/biology13090690 |
0.62 |
|
| 2022 |
Moriarty N, Gantner CW, Hunt CPJ, Ermine CM, Frausin S, Viventi S, Ovchinnikov DA, Kirik D, Parish CL, Thompson LH. A combined cell and gene therapy approach for homotopic reconstruction of midbrain dopamine pathways using human pluripotent stem cells. Cell Stem Cell. PMID 35180398 DOI: 10.1016/j.stem.2022.01.013 |
0.669 |
|
| 2020 |
Marmion DJ, Rutkowski AA, Chatterjee D, Hiller BM, Werner MH, Bezard E, Kirik D, McCown T, Gray SJ, Kordower JH. Viral-based rodent and nonhuman primate models of multiple system atrophy: Fidelity to the human disease. Neurobiology of Disease. 105184. PMID 33221532 DOI: 10.1016/j.nbd.2020.105184 |
0.376 |
|
| 2020 |
Landeck N, Strathearn KE, Ysselstein D, Buck K, Dutta S, Banerjee S, Lv Z, Hulleman JD, Hindupur J, Lin LK, Padalkar S, Stanciu LA, Lyubchenko YL, Kirik D, Rochet JC. Two C-terminal sequence variations determine differential neurotoxicity between human and mouse α-synuclein. Molecular Neurodegeneration. 15: 49. PMID 32900375 DOI: 10.1186/S13024-020-00380-W |
0.356 |
|
| 2020 |
Gantner CW, de Luzy IR, Kauhausen JA, Moriarty N, Niclis JC, Bye CR, Penna V, Hunt CPJ, Ermine CM, Pouton CW, Kirik D, Thompson LH, Parish CL. Viral Delivery of GDNF Promotes Functional Integration of Human Stem Cell Grafts in Parkinson's Disease. Cell Stem Cell. PMID 32059808 DOI: 10.1016/J.Stem.2020.01.010 |
0.684 |
|
| 2019 |
Elfarrash S, Jensen NM, Ferreira N, Betzer C, Thevathasan JV, Diekmann R, Adel M, Omar NM, Boraie MZ, Gad S, Ries J, Kirik D, Nabavi S, Jensen PH. Organotypic slice culture model demonstrates inter-neuronal spreading of alpha-synuclein aggregates. Acta Neuropathologica Communications. 7: 213. PMID 31856920 DOI: 10.1186/S40478-019-0865-5 |
0.331 |
|
| 2019 |
Stefanis L, Emmanouilidou E, Pantazopoulou M, Kirik D, Vekrellis K, Tofaris GK. How is alpha-synuclein cleared from the cell? Journal of Neurochemistry. PMID 31069800 DOI: 10.1111/Jnc.14704 |
0.328 |
|
| 2018 |
Lillethorup TP, Glud AN, Alstrup AKO, Noer O, Nielsen EHT, Schacht AC, Landeck N, Kirik D, Orlowski D, Sørensen JCH, Doudet DJ, Landau AM. Longitudinal monoaminergic PET imaging of chronic proteasome inhibition in minipigs. Scientific Reports. 8: 15715. PMID 30356172 DOI: 10.1038/S41598-018-34084-5 |
0.312 |
|
| 2018 |
Pinholt Lillethorup T, Glud AN, Landeck N, Alstrup AKO, Jakobsen S, Vang K, Doudet DJ, Brooks DJ, Kirik D, Hinz R, Sørensen JC, Landau AM. In vivo Quantification of Glial Activation in Minipigs Overexpressing human α-synuclein. Synapse (New York, N.Y.). PMID 30009467 DOI: 10.1002/Syn.22060 |
0.427 |
|
| 2018 |
Gabery S, Baldo B, Soylu-Kucharz R, Cheong RY, Henningsen JB, Englund E, McLean C, Kirik D, Halliday G, Petersén Å. A52 SIRT1 is increased in affected brain regions in huntington disease impacting hypothalamic metabolic pathways Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.50 |
0.338 |
|
| 2018 |
Cheong RY, Cuellar-Baena S, Baldo B, Zandt Ri‘, Kirik D, Petersén Å. A44 Analysis of the deletion of mutant huntingtin from A2A-receptor expressing neurons Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.42 |
0.424 |
|
| 2017 |
Mandel RJ, Marmion DJ, Kirik D, Chu Y, Heindel C, McCown T, Gray SJ, Kordower JH. Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates. Acta Neuropathologica Communications. 5: 47. PMID 28619074 DOI: 10.1186/S40478-017-0451-7 |
0.425 |
|
| 2016 |
Landeck N, Buck K, Kirik D. Toxic effects of human and rodent variants of alpha-synuclein in vivo. The European Journal of Neuroscience. PMID 27893183 DOI: 10.1111/Ejn.13493 |
0.376 |
|
| 2016 |
Kirik D, Cederfjäll E, Halliday G, Petersén Å. Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. Neurobiology of Disease. PMID 27616425 DOI: 10.1016/J.Nbd.2016.09.008 |
0.823 |
|
| 2016 |
Naughton C, O'Toole D, Kirik D, Dowd E. Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats. Behavioural Brain Research. PMID 27585560 DOI: 10.1016/J.Bbr.2016.08.056 |
0.408 |
|
| 2016 |
Landeck N, Hall H, Ardah MT, Majbour NK, El-Agnaf OM, Halliday G, Kirik D. A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein. Molecular Neurodegeneration. 11: 61. PMID 27549140 DOI: 10.1186/S13024-016-0125-0 |
0.485 |
|
| 2016 |
Volpicelli-Daley LA, Kirik D, Stoyka LE, Standaert DG, Harms AS. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson disease? Journal of Neurochemistry. PMID 27018978 DOI: 10.1111/Jnc.13627 |
0.381 |
|
| 2016 |
Cuellar-Baena S, Landeck N, Sonnay S, Buck K, Mlynarik V, Zandt RI, Kirik D. Assessment of brain metabolite correlates of AAV-mediated overexpression of human alpha-synuclein in cortical neurons by in vivo(1) H-MR spectroscopy at 9.4 T. Journal of Neurochemistry. PMID 26811128 DOI: 10.1111/Jnc.13547 |
0.382 |
|
| 2015 |
Kuzdas-Wood D, Fellner L, Premstaller M, Borm C, Bloem B, Kirik D, Wenning GK, Stefanova N. Overexpression of α-synuclein in oligodendrocytes does not increase susceptibility to focal striatal excitotoxicity. Bmc Neuroscience. 16: 86. PMID 26627686 DOI: 10.1186/S12868-015-0227-6 |
0.442 |
|
| 2015 |
Soylu-Kucharz R, Adlesic N, Baldo B, Kirik D, Petersén Å. Hypothalamic overexpression of mutant huntingtin causes dysregulation of brown adipose tissue. Scientific Reports. 5: 14598. PMID 26419281 DOI: 10.1038/Srep14598 |
0.348 |
|
| 2015 |
Buck K, Landeck N, Ulusoy A, Majbour NK, El-Agnaf OM, Kirik D. Ser129 phosphorylation of endogenous α-synuclein induced by overexpression of polo-like kinases 2 and 3 in nigral dopamine neurons is not detrimental to their survival and function. Neurobiology of Disease. 78: 100-14. PMID 25818009 DOI: 10.1016/J.Nbd.2015.03.008 |
0.39 |
|
| 2015 |
Cederfjäll E, Broom L, Kirik D. Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 896-906. PMID 25592335 DOI: 10.1038/Mt.2015.8 |
0.826 |
|
| 2014 |
Hall H, Reyes S, Landeck N, Bye C, Leanza G, Double K, Thompson L, Halliday G, Kirik D. Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. Brain : a Journal of Neurology. 137: 2493-508. PMID 25062696 DOI: 10.1093/Brain/Awu193 |
0.787 |
|
| 2014 |
Sahin G, Thompson LH, Lavisse S, Ozgur M, Rbah-Vidal L, Dollé F, Hantraye P, Kirik D. Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of Parkinson's disease. Plos One. 9: e90759. PMID 24614598 DOI: 10.1371/Journal.Pone.0090759 |
0.685 |
|
| 2014 |
Ledri M, Madsen MG, Nikitidou L, Kirik D, Kokaia M. Global optogenetic activation of inhibitory interneurons during epileptiform activity. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 3364-77. PMID 24573293 DOI: 10.1523/Jneurosci.2734-13.2014 |
0.314 |
|
| 2014 |
Moloney TC, Hyland R, O'Toole D, Paucard A, Kirik D, O'Doherty A, Gorman AM, Dowd E. Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease. Cns Neuroscience & Therapeutics. 20: 50-8. PMID 24279716 DOI: 10.1111/Cns.12200 |
0.494 |
|
| 2014 |
Gabery S, Soylu-Kucharz R, McLean C, Kirik D, Halliday G, Petersen A. H04 Gene Expression Changes In Emotion And Metabolism Regulating Neuropeptide Systems In The Hypothalamus In Clinical Huntington Disease Journal of Neurology, Neurosurgery & Psychiatry. 85: A53-A53. DOI: 10.1136/Jnnp-2014-309032.149 |
0.359 |
|
| 2013 |
Xilouri M, Brekk OR, Kirik D, Stefanis L. LAMP2A as a therapeutic target in Parkinson disease. Autophagy. 9: 2166-8. PMID 24145820 DOI: 10.4161/Auto.26451 |
0.423 |
|
| 2013 |
Cederfjäll E, Nilsson N, Sahin G, Chu Y, Nikitidou E, Björklund T, Kordower JH, Kirik D. Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Scientific Reports. 3: 2157. PMID 23831692 DOI: 10.1038/Srep02157 |
0.802 |
|
| 2013 |
Xilouri M, Brekk OR, Landeck N, Pitychoutis PM, Papasilekas T, Papadopoulou-Daifoti Z, Kirik D, Stefanis L. Boosting chaperone-mediated autophagy in vivo mitigates α-synuclein-induced neurodegeneration. Brain : a Journal of Neurology. 136: 2130-46. PMID 23757764 DOI: 10.1093/Brain/Awt131 |
0.46 |
|
| 2013 |
Hall H, Jewett M, Landeck N, Nilsson N, Schagerlöf U, Leanza G, Kirik D. Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors. Plos One. 8: e64844. PMID 23705016 DOI: 10.1371/Journal.Pone.0064844 |
0.751 |
|
| 2013 |
Hult Lundh S, Nilsson N, Soylu R, Kirik D, Petersén Å. Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease. Human Molecular Genetics. 22: 3485-97. PMID 23697793 DOI: 10.1093/Hmg/Ddt203 |
0.31 |
|
| 2013 |
Reyes S, Cottam V, Kirik D, Double KL, Halliday GM. Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1351-9. PMID 23674405 DOI: 10.1002/Mds.25493 |
0.469 |
|
| 2013 |
Febbraro F, Sahin G, Farran A, Soares S, Jensen PH, Kirik D, Romero-Ramos M. Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease. Neurobiology of Disease. 56: 47-58. PMID 23567651 DOI: 10.1016/J.Nbd.2013.03.014 |
0.727 |
|
| 2013 |
Mulcahy P, O'Doherty A, Paucard A, O'Brien T, Kirik D, Dowd E. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats. Behavioural Brain Research. 243: 6-15. PMID 23295396 DOI: 10.1016/J.Bbr.2012.12.051 |
0.456 |
|
| 2013 |
Hall H, Cuellar-Baena S, Denisov V, Kirik D. Development of NMR spectroscopic methods for dynamic detection of acetylcholine synthesis by choline acetyltransferase in hippocampal tissue. Journal of Neurochemistry. 124: 336-46. PMID 23004566 DOI: 10.1111/Jnc.12025 |
0.444 |
|
| 2013 |
Oksman M, Wisman LA, Jiang H, Miettinen P, Kirik D, Tanila H. Transduced wild-type but not P301S mutated human tau shows hyperphosphorylation in transgenic mice overexpressing A30P mutated human alpha-synuclein. Neuro-Degenerative Diseases. 12: 91-102. PMID 22948283 DOI: 10.1159/000341596 |
0.304 |
|
| 2013 |
Reyes S, Fu Y, Double KL, Cottam V, Thompson LH, Kirik D, Paxinos G, Watson C, Cooper HM, Halliday GM. Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease. Neurobiology of Aging. 34: 873-86. PMID 22926168 DOI: 10.1016/J.Neurobiolaging.2012.07.019 |
0.701 |
|
| 2013 |
Bezard E, Yue Z, Kirik D, Spillantini MG. Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 61-70. PMID 22753348 DOI: 10.1002/Mds.25108 |
0.463 |
|
| 2013 |
Febbraro F, Sahin G, Farran A, Soares S, Jensen PH, Kirik D, Romero-Ramos M. Corrigendum to "Ser129D mutant alpha-synuclein induces earlier motor dysfunction while S129A results in distinctive pathology in a rat model of Parkinson's disease" [Neurobiol. Dis. 56 (2013) 48-58] Neurobiology of Disease. 58: 191. DOI: 10.1016/J.Nbd.2013.06.003 |
0.703 |
|
| 2012 |
Gabery S, Sajjad MU, Hult S, Soylu R, Kirik D, Petersén Å. Characterization of a rat model of Huntington's disease based on targeted expression of mutant huntingtin in the forebrain using adeno-associated viral vectors. The European Journal of Neuroscience. 36: 2789-800. PMID 22731249 DOI: 10.1111/J.1460-9568.2012.08193.X |
0.439 |
|
| 2012 |
Ulusoy A, Björklund T, Buck K, Kirik D. Dysregulated dopamine storage increases the vulnerability to α-synuclein in nigral neurons. Neurobiology of Disease. 47: 367-77. PMID 22659302 DOI: 10.1016/J.Nbd.2012.05.012 |
0.504 |
|
| 2012 |
Lastres-Becker I, Ulusoy A, Innamorato NG, Sahin G, Rábano A, Kirik D, Cuadrado A. α-Synuclein expression and Nrf2 deficiency cooperate to aggravate protein aggregation, neuronal death and inflammation in early-stage Parkinson's disease. Human Molecular Genetics. 21: 3173-92. PMID 22513881 DOI: 10.1093/Hmg/Dds143 |
0.446 |
|
| 2012 |
Barkholt P, Sanchez-Guajardo V, Kirik D, Romero-Ramos M. Long-term polarization of microglia upon α-synuclein overexpression in nonhuman primates. Neuroscience. 208: 85-96. PMID 22342967 DOI: 10.1016/J.Neuroscience.2012.02.004 |
0.714 |
|
| 2012 |
Cederfjäll E, Sahin G, Kirik D, Björklund T. Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 1315-26. PMID 22294150 DOI: 10.1038/Mt.2012.1 |
0.84 |
|
| 2012 |
Reyes S, Fu Y, Double K, Thompson L, Kirik D, Paxinos G, Halliday GM. GIRK2 expression in dopamine neurons of the substantia nigra and ventral tegmental area. The Journal of Comparative Neurology. 520: 2591-607. PMID 22252428 DOI: 10.1002/Cne.23051 |
0.644 |
|
| 2012 |
Mulcahy P, O'Doherty A, Paucard A, O'Brien T, Kirik D, Dowd E. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone. Neuroscience. 203: 170-9. PMID 22198020 DOI: 10.1016/J.Neuroscience.2011.12.011 |
0.454 |
|
| 2012 |
Hall H, Cuellar-Baena S, Dahlberg C, In't Zandt R, Denisov V, Kirik D. Magnetic resonance spectroscopic methods for the assessment of metabolic functions in the diseased brain. Current Topics in Behavioral Neurosciences. 11: 169-98. PMID 22076698 DOI: 10.1007/7854_2011_166 |
0.44 |
|
| 2012 |
Xilouri M, Kyratzi E, Pitychoutis PM, Papadopoulou-Daifoti Z, Perier C, Vila M, Maniati M, Ulusoy A, Kirik D, Park DS, Wada K, Stefanis L. Selective neuroprotective effects of the S18Y polymorphic variant of UCH-L1 in the dopaminergic system. Human Molecular Genetics. 21: 874-89. PMID 22076440 DOI: 10.1093/Hmg/Ddr521 |
0.417 |
|
| 2012 |
Cederfjäll E, Sahin G, Kirik D. Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain. Neurobiology of Disease. 48: 222-7. PMID 22048069 DOI: 10.1016/J.Nbd.2011.10.017 |
0.83 |
|
| 2012 |
Sajjad M, Pinard G, Fafard C, Illy C, Petersén Å, Kirik D. F01 Establishment of novel assays for quantification of full-length wild-type and mutant huntingtin by using the alphalisa technology Journal of Neurology, Neurosurgery & Psychiatry. 83: A21.2-A21. DOI: 10.1136/Jnnp-2012-303524.66 |
0.331 |
|
| 2012 |
Gabery S, Sajjad M, Hult S, Soylu R, Kirik D, Petersén Å. C09 Characterisation of a rat model of Huntington's disease based on targeted expression of a mutant huntingtin fragment in the forebrain using an adeno-associated viral vector Journal of Neurology, Neurosurgery & Psychiatry. 83: A18.1-A18. DOI: 10.1136/Jnnp-2012-303524.56 |
0.399 |
|
| 2011 |
Ulusoy A, Kirik D. Development of advanced therapies based on viral vector-mediated overexpression of therapeutic molecules and knockdown of disease-related genes for Parkinson's disease. Therapeutic Delivery. 2: 37-50. PMID 22833924 DOI: 10.4155/Tde.10.95 |
0.434 |
|
| 2011 |
Decressac M, Ulusoy A, Mattsson B, Georgievska B, Romero-Ramos M, Kirik D, Björklund A. GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. Brain : a Journal of Neurology. 134: 2302-11. PMID 21712347 DOI: 10.1093/Brain/Awr149 |
0.832 |
|
| 2011 |
Hult S, Soylu R, Björklund T, Belgardt BF, Mauer J, Brüning JC, Kirik D, Petersén Å. Mutant huntingtin causes metabolic imbalance by disruption of hypothalamic neurocircuits. Cell Metabolism. 13: 428-39. PMID 21459327 DOI: 10.1016/J.Cmet.2011.02.013 |
0.311 |
|
| 2010 |
Dodiya HB, Bjorklund T, Stansell Iii J, Mandel RJ, Kirik D, Kordower JH. Differential Transduction Following Basal Ganglia Administration of Distinct Pseudotyped AAV Capsid Serotypes in Nonhuman Primates. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 579-587. PMID 28182881 DOI: 10.1038/mt.2009.216 |
0.376 |
|
| 2010 |
Björklund T, Cederfjäll EA, Kirik D. Gene therapy for dopamine replacement. Progress in Brain Research. 184: 221-35. PMID 20887878 DOI: 10.1016/S0079-6123(10)84012-9 |
0.827 |
|
| 2010 |
Ulusoy A, Decressac M, Kirik D, Björklund A. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease. Progress in Brain Research. 184: 89-111. PMID 20887871 DOI: 10.1016/S0079-6123(10)84005-1 |
0.8 |
|
| 2010 |
Iwamoto M, Björklund T, Lundberg C, Kirik D, Wandless TJ. A general chemical method to regulate protein stability in the mammalian central nervous system. Chemistry & Biology. 17: 981-8. PMID 20851347 DOI: 10.1016/J.Chembiol.2010.07.009 |
0.532 |
|
| 2010 |
Gabery S, Murphy K, Schultz K, Loy CT, McCusker E, Kirik D, Halliday G, Petersén A. Changes in key hypothalamic neuropeptide populations in Huntington disease revealed by neuropathological analyses. Acta Neuropathologica. 120: 777-88. PMID 20821223 DOI: 10.1007/S00401-010-0742-6 |
0.389 |
|
| 2010 |
Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M. Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology. The European Journal of Neuroscience. 32: 409-22. PMID 20704592 DOI: 10.1111/J.1460-9568.2010.07284.X |
0.722 |
|
| 2010 |
Soneson C, Fontes M, Zhou Y, Denisov V, Paulsen JS, Kirik D, Petersén A. Early changes in the hypothalamic region in prodromal Huntington disease revealed by MRI analysis. Neurobiology of Disease. 40: 531-43. PMID 20682340 DOI: 10.1016/J.Nbd.2010.07.013 |
0.308 |
|
| 2010 |
Ulusoy A, Sahin G, Kirik D. Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proceedings of the National Academy of Sciences of the United States of America. 107: 13159-64. PMID 20615977 DOI: 10.1073/Pnas.1003432107 |
0.464 |
|
| 2010 |
Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A. Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: S174-9. PMID 20187238 DOI: 10.1002/Mds.22792 |
0.765 |
|
| 2010 |
Björklund T, Carlsson T, Cederfjäll EA, Carta M, Kirik D. Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain : a Journal of Neurology. 133: 496-511. PMID 20129936 DOI: 10.1093/Brain/Awp314 |
0.829 |
|
| 2010 |
Grealish S, Jönsson ME, Li M, Kirik D, Björklund A, Thompson LH. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. Brain : a Journal of Neurology. 133: 482-95. PMID 20123725 DOI: 10.1093/Brain/Awp328 |
0.822 |
|
| 2010 |
Sanchez-Guajardo V, Febbraro F, Kirik D, Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. Plos One. 5: e8784. PMID 20098715 DOI: 10.1371/Journal.Pone.0008784 |
0.708 |
|
| 2010 |
Kornum BR, Stott SR, Mattsson B, Wisman L, Ettrup A, Hermening S, Knudsen GM, Kirik D. Adeno-associated viral vector serotypes 1 and 5 targeted to the neonatal rat and pig striatum induce widespread transgene expression in the forebrain. Experimental Neurology. 222: 70-85. PMID 20025873 DOI: 10.1016/J.Expneurol.2009.12.009 |
0.436 |
|
| 2010 |
Dodiya HB, Bjorklund T, Stansell J, Mandel RJ, Kirik D, Kordower JH. Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 579-87. PMID 19773746 DOI: 10.1038/Mt.2009.216 |
0.734 |
|
| 2010 |
Soylu R, Hult S, Björklund T, Belgardt BF, Mauer J, Brüning JC, Kirik D, Petersén Å. A24 Hypothalamic expression of mutant huntingtin causes metabolic disturbances in mice Journal of Neurology, Neurosurgery & Psychiatry. 81: A8.1-A8. DOI: 10.1136/Jnnp.2010.222570.24 |
0.647 |
|
| 2010 |
Gabery S, Murphy K, Schultz K, Loy CT, McCusker E, Kirik D, Halliday G, Petersén Å. A23 Changes in key hypothalamic neuropeptide populations in Huntington's Disease revealed by neuropathological analyses Journal of Neurology, Neurosurgery, and Psychiatry. 81. DOI: 10.1136/Jnnp.2010.222570.23 |
0.379 |
|
| 2010 |
Kirik D, Björklund MT, Ramaswamy S, Kordower JH. Novel Gene-Based Therapeutics Targeting the Dopaminergic System in Parkinson's Disease Dopamine Handbook. DOI: 10.1093/acprof:oso/9780195373035.003.0034 |
0.323 |
|
| 2009 |
Björklund A, Björklund T, Kirik D. Gene therapy for dopamine replacement in Parkinson's disease. Science Translational Medicine. 1: 2ps2. PMID 20368161 DOI: 10.1126/Scitranslmed.3000350 |
0.741 |
|
| 2009 |
Wilms H, Rosenstiel P, Romero-Ramos M, Arlt A, Schäfer H, Seegert D, Kahle PJ, Odoy S, Claasen JH, Holzknecht C, Brandenburg LO, Deuschl G, Schreiber S, Kirik D, Lucius R. Suppression of MAP kinases inhibits microglial activation and attenuates neuronal cell death induced by alpha-synuclein protofibrils. International Journal of Immunopathology and Pharmacology. 22: 897-909. PMID 20074453 |
0.638 |
|
| 2009 |
Sarkar R, Comment A, Vasos PR, Jannin S, Gruetter R, Bodenhausen G, Hall H, Kirik D, Denisov VP. Proton NMR of (15)N-choline metabolites enhanced by dynamic nuclear polarization. Journal of the American Chemical Society. 131: 16014-5. PMID 19848401 DOI: 10.1021/Ja9021304 |
0.352 |
|
| 2009 |
Björklund T, Hall H, Breysse N, Soneson C, Carlsson T, Mandel RJ, Carta M, Kirik D. Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats. Journal of Neurochemistry. 111: 355-67. PMID 19686242 DOI: 10.1111/J.1471-4159.2009.06340.X |
0.811 |
|
| 2009 |
Thompson LH, Grealish S, Kirik D, Björklund A. Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. The European Journal of Neuroscience. 30: 625-38. PMID 19674082 DOI: 10.1111/J.1460-9568.2009.06878.X |
0.846 |
|
| 2009 |
Ulusoy A, Sahin G, Björklund T, Aebischer P, Kirik D. Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1574-84. PMID 19584816 DOI: 10.1038/Mt.2009.142 |
0.471 |
|
| 2009 |
Petersén A, Hult S, Kirik D. Huntington's disease - new perspectives based on neuroendocrine changes in rodent models. Neuro-Degenerative Diseases. 6: 154-64. PMID 19521064 DOI: 10.1159/000225377 |
0.346 |
|
| 2009 |
Muñoz A, Carlsson T, Tronci E, Kirik D, Björklund A, Carta M. Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and 5-HT1B receptor agonists in the rat Parkinson model. Experimental Neurology. 219: 298-307. PMID 19500572 DOI: 10.1016/J.Expneurol.2009.05.033 |
0.684 |
|
| 2009 |
Björklund T, Kirik D. Scientific rationale for the development of gene therapy strategies for Parkinson's disease. Biochimica Et Biophysica Acta. 1792: 703-13. PMID 19254760 DOI: 10.1016/J.Bbadis.2009.02.009 |
0.472 |
|
| 2009 |
Leriche L, Björklund T, Breysse N, Besret L, Grégoire MC, Carlsson T, Dollé F, Mandel RJ, Déglon N, Hantraye P, Kirik D. Positron emission tomography imaging demonstrates correlation between behavioral recovery and correction of dopamine neurotransmission after gene therapy. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 1544-53. PMID 19193901 DOI: 10.1523/Jneurosci.4491-08.2009 |
0.816 |
|
| 2009 |
Carlsson T, Carta M, Muñoz A, Mattsson B, Winkler C, Kirik D, Björklund A. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain : a Journal of Neurology. 132: 319-35. PMID 19039008 DOI: 10.1093/Brain/Awn305 |
0.798 |
|
| 2009 |
Kirik D, Ulusoy A. Are the animal models of Parkinson's disease suitable for development of neuroprotective therapies? Journal of Neurochemistry. 110: 63-63. DOI: 10.1111/J.1471-4159.2009.06064_17.X |
0.417 |
|
| 2008 |
Lundberg C, Björklund T, Carlsson T, Jakobsson J, Hantraye P, Déglon N, Kirik D. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Current Gene Therapy. 8: 461-73. PMID 19075629 DOI: 10.2174/156652308786847996 |
0.788 |
|
| 2008 |
Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain : a Journal of Neurology. 131: 3380-94. PMID 18952677 DOI: 10.1093/Brain/Awn235 |
0.698 |
|
| 2008 |
Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A. Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias. Progress in Brain Research. 172: 465-78. PMID 18772046 DOI: 10.1016/S0079-6123(08)00922-9 |
0.74 |
|
| 2008 |
Wisman LA, Sahin G, Maingay M, Leanza G, Kirik D. Functional convergence of dopaminergic and cholinergic input is critical for hippocampus-dependent working memory. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 7797-807. PMID 18667612 DOI: 10.1523/Jneurosci.1885-08.2008 |
0.659 |
|
| 2008 |
Thompson LH, Kirik D, Björklund A. Non-dopaminergic neurons in ventral mesencephalic transplants make widespread axonal connections in the host brain. Experimental Neurology. 213: 220-8. PMID 18602916 DOI: 10.1016/J.Expneurol.2008.06.005 |
0.691 |
|
| 2008 |
Carta M, Carlsson T, Muñoz A, Kirik D, Björklund A. Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism & Related Disorders. 14: S154-8. PMID 18579429 DOI: 10.1016/J.Parkreldis.2008.04.021 |
0.758 |
|
| 2008 |
Ulusoy A, Kirik D. Can overexpression of parkin provide a novel strategy for neuroprotection in Parkinson's disease? Experimental Neurology. 212: 258-60. PMID 18538324 DOI: 10.1016/J.Expneurol.2008.04.026 |
0.487 |
|
| 2008 |
Irvin DK, Kirik D, Björklund A, Thompson LH. In vivo gene delivery to proliferating cells in the striatum generated in response to a 6-hydroxydopamine lesion of the nigro-striatal dopamine pathway. Neurobiology of Disease. 30: 343-52. PMID 18417351 DOI: 10.1016/J.Nbd.2008.02.006 |
0.816 |
|
| 2008 |
Ulusoy A, Bjorklund T, Hermening S, Kirik D. In vivo gene delivery for development of mammalian models for Parkinson's disease. Experimental Neurology. 209: 89-100. PMID 18028909 DOI: 10.1016/J.Expneurol.2007.09.011 |
0.731 |
|
| 2008 |
Lane EL, Carlsson T, Kirik D, Dunnett SB. Animal models of Parkinson's disease Source Book of Models For Biomedical Research. 313-322. DOI: 10.1007/978-1-59745-285-4_34 |
0.772 |
|
| 2008 |
Björklund T, Morizane A, Kirik D, Brundin P. Future Cell-and Gene-Based Therapies for Parkinson's Disease Therapeutics of Parkinson's Disease and Other Movement Disorders. 145-156. DOI: 10.1002/9780470713990.ch8 |
0.727 |
|
| 2007 |
Enquist IB, Lo Bianco C, Ooka A, Nilsson E, MÃ¥nsson JE, Ehinger M, Richter J, Brady RO, Kirik D, Karlsson S. Murine models of acute neuronopathic Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America. 104: 17483-8. PMID 17954912 DOI: 10.1073/Pnas.0708086104 |
0.376 |
|
| 2007 |
Carlsson T, Carta M, Winkler C, Björklund A, Kirik D. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 8011-22. PMID 17652591 DOI: 10.1523/Jneurosci.2079-07.2007 |
0.798 |
|
| 2007 |
Breysse N, Carlsson T, Winkler C, Björklund A, Kirik D. The functional impact of the intrastriatal dopamine neuron grafts in parkinsonian rats is reduced with advancing disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 5849-56. PMID 17537955 DOI: 10.1523/Jneurosci.0626-07.2007 |
0.833 |
|
| 2007 |
Kanter-Schlifke I, Georgievska B, Kirik D, Kokaia M. Brain area, age and viral vector-specific glial cell-line-derived neurotrophic factor expression and transport in rat. Neuroreport. 18: 845-50. PMID 17515788 DOI: 10.1097/Wnr.0B013E32811E1506 |
0.35 |
|
| 2007 |
Carta M, Carlsson T, Kirik D, Björklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain : a Journal of Neurology. 130: 1819-33. PMID 17452372 DOI: 10.1093/Brain/Awm082 |
0.748 |
|
| 2007 |
Carlsson T, Björklund T, Kirik D. Restoration of the striatal dopamine synthesis for Parkinson's disease: viral vector-mediated enzyme replacement strategy. Current Gene Therapy. 7: 109-20. PMID 17430130 DOI: 10.2174/156652307780363125 |
0.702 |
|
| 2007 |
Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain : a Journal of Neurology. 130: 799-815. PMID 17303591 DOI: 10.1093/Brain/Awl382 |
0.784 |
|
| 2006 |
Stott SR, Kirik D. Targeted in utero delivery of a retroviral vector for gene transfer in the rodent brain. The European Journal of Neuroscience. 24: 1897-906. PMID 17067293 DOI: 10.1111/J.1460-9568.2006.05095.X |
0.438 |
|
| 2006 |
Maingay M, Romero-Ramos M, Carta M, Kirik D. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression. Neurobiology of Disease. 23: 522-32. PMID 16806952 DOI: 10.1016/J.Nbd.2006.04.007 |
0.79 |
|
| 2006 |
Torres EM, Meldrum A, Kirik D, Dunnett SB. An investigation of the problem of two-layered immunohistochemical staining in paraformaldehyde fixed sections. Journal of Neuroscience Methods. 158: 64-74. PMID 16797719 DOI: 10.1016/J.Jneumeth.2006.05.016 |
0.422 |
|
| 2006 |
Winkler C, Georgievska B, Carlsson T, Lacar B, Kirik D. Continuous exposure to glial cell line-derived neurotrophic factor to mature dopaminergic transplants impairs the graft's ability to improve spontaneous motor behavior in parkinsonian rats. Neuroscience. 141: 521-31. PMID 16697115 DOI: 10.1016/J.Neuroscience.2006.03.068 |
0.833 |
|
| 2006 |
Carlsson T, Winkler C, Lundblad M, Cenci MA, Björklund A, Kirik D. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiology of Disease. 21: 657-68. PMID 16256359 DOI: 10.1016/J.Nbd.2005.09.008 |
0.708 |
|
| 2005 |
Kirik D, Björklund A. Parkinson's disease: viral vector delivery of parkin generates model results in rats. Gene Therapy. 12: 727-9. PMID 19202633 DOI: 10.1038/Sj.Gt.3302497 |
0.425 |
|
| 2005 |
Kirik D, Breysse N, Björklund T, Besret L, Hantraye P. Imaging in cell-based therapy for neurodegenerative diseases. European Journal of Nuclear Medicine and Molecular Imaging. 32: S417-34. PMID 16267643 DOI: 10.1007/S00259-005-1909-6 |
0.792 |
|
| 2005 |
Barraud P, Thompson L, Kirik D, Björklund A, Parmar M. Isolation and characterization of neural precursor cells from the Sox1-GFP reporter mouse. The European Journal of Neuroscience. 22: 1555-69. PMID 16197496 DOI: 10.1111/J.1460-9568.2005.04352.X |
0.681 |
|
| 2005 |
Thompson L, Barraud P, Andersson E, Kirik D, Björklund A. Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 6467-77. PMID 16000637 DOI: 10.1523/Jneurosci.1676-05.2005 |
0.774 |
|
| 2005 |
Kirik D, Björklund A. Histological analysis of fetal dopamine cell suspension grafts in two patients with Parkinson's disease gives promising results. Brain : a Journal of Neurology. 128: 1478-9. PMID 15980119 DOI: 10.1093/Brain/Awh570 |
0.452 |
|
| 2005 |
Sørensen AT, Thompson L, Kirik D, Björklund A, Lindvall O, Kokaia M. Functional properties and synaptic integration of genetically labelled dopaminergic neurons in intrastriatal grafts. The European Journal of Neuroscience. 21: 2793-9. PMID 15926926 DOI: 10.1111/J.1460-9568.2005.04116.X |
0.749 |
|
| 2005 |
Popovic N, Maingay M, Kirik D, Brundin P. Lentiviral gene delivery of GDNF into the striatum of R6/2 Huntington mice fails to attenuate behavioral and neuropathological changes. Experimental Neurology. 193: 65-74. PMID 15817265 DOI: 10.1016/J.Expneurol.2004.12.009 |
0.561 |
|
| 2005 |
Maingay M, Romero-Ramos M, Kirik D. Viral vector mediated overexpression of human alpha-synuclein in the nigrostriatal dopaminergic neurons: a new model for Parkinson's disease. Cns Spectrums. 10: 235-44. PMID 15744224 DOI: 10.1017/S1092852900010075 |
0.773 |
|
| 2005 |
Eslamboli A, Georgievska B, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Annett L, Kirik D. Continuous low-level glial cell line-derived neurotrophic factor delivery using recombinant adeno-associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 769-77. PMID 15673656 DOI: 10.1523/Jneurosci.4421-04.2005 |
0.515 |
|
| 2005 |
Winkler C, Kirik D, Björklund A. Cell transplantation in Parkinson's disease: how can we make it work? Trends in Neurosciences. 28: 86-92. PMID 15667931 DOI: 10.1016/J.Tins.2004.12.006 |
0.58 |
|
| 2005 |
Carlsson T, Winkler C, Burger C, Muzyczka N, Mandel RJ, Cenci A, Björklund A, Kirik D. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors. Brain : a Journal of Neurology. 128: 559-69. PMID 15659429 DOI: 10.1093/Brain/Awh374 |
0.82 |
|
| 2005 |
Winkler C, Carlsson T, Burger C, Muzyczka N, Mandel R, Cenci A, Björklund A, Dengler R, Kirik D. Normalisierung der striatalen Genexpression und Reduktion L-DOPA-induzierter Dyskinesien durch viralen Gentransfer im Tiermodell der Parkinson'schen Erkrankung Aktuelle Neurologie. 32. DOI: 10.1055/S-2005-866631 |
0.666 |
|
| 2005 |
Georgievska B, Winkler C, Carlsson T, Lacar B, Kirik D. 941. Delayed GDNF Exposure to Mature Dopaminergic Grafts Impairs Their Ability To Improve Motor Function in Parkinsonian Rats Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.07.484 |
0.815 |
|
| 2004 |
Georgievska B, Jakobsson J, Persson E, Ericson C, Kirik D, Lundberg C. Regulated delivery of glial cell line-derived neurotrophic factor into rat striatum, using a tetracycline-dependent lentiviral vector. Human Gene Therapy. 15: 934-44. PMID 15585109 DOI: 10.1089/Hum.2004.15.934 |
0.712 |
|
| 2004 |
Georgievska B, Carlsson T, Lacar B, Winkler C, Kirik D. Dissociation between short-term increased graft survival and long-term functional improvements in Parkinsonian rats overexpressing glial cell line-derived neurotrophic factor. The European Journal of Neuroscience. 20: 3121-30. PMID 15579166 DOI: 10.1111/J.1460-9568.2004.03770.X |
0.813 |
|
| 2004 |
Georgievska B, Kirik D, Björklund A. Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 24: 6437-45. PMID 15269253 DOI: 10.1523/Jneurosci.1122-04.2004 |
0.502 |
|
| 2004 |
Kirik D, Georgievska B, Björklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nature Neuroscience. 7: 105-10. PMID 14747832 DOI: 10.1038/Nn1175 |
0.465 |
|
| 2004 |
Nygren JM, Stott S, Liuba K, Breitbach M, Röll W, Fleischmann B, Kirik D, Björklund A, Jacobsen SEW. Adult Bone Marrow-Derived Cell Fusion with Cardiomyocytes and Purkinje Neurons in Response to Irradiation but Not in Steady State. Blood. 104: 3604-3604. DOI: 10.1182/Blood.V104.11.3604.3604 |
0.34 |
|
| 2004 |
Winkler C, Carlsson T, Burger C, Muzyczka N, Mandel R, Cenci A, Dengler R, Björklund A, Kirik D. Reversal of L-DOPA-induced dyskinesia by recombinant AAV-mediated gene transfer Aktuelle Neurologie. 31. DOI: 10.1055/S-2004-833029 |
0.655 |
|
| 2003 |
Arvidsson A, Kirik D, Lundberg C, Mandel RJ, Andsberg G, Kokaia Z, Lindvall O. Elevated GDNF levels following viral vector-mediated gene transfer can increase neuronal death after stroke in rats. Neurobiology of Disease. 14: 542-56. PMID 14678770 DOI: 10.1016/J.Nbd.2003.08.002 |
0.716 |
|
| 2003 |
Eslamboli A, Cummings RM, Ridley RM, Baker HF, Muzyczka N, Burger C, Mandel RJ, Kirik D, Annett LE. Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Experimental Neurology. 184: 536-48. PMID 14637123 DOI: 10.1016/J.Expneurol.2003.08.007 |
0.514 |
|
| 2003 |
Kirik D, Björklund A. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends in Neurosciences. 26: 386-92. PMID 12850435 DOI: 10.1016/S0166-2236(03)00164-4 |
0.486 |
|
| 2003 |
Gustafsson E, Andsberg G, Darsalia V, Mohapel P, Mandel RJ, Kirik D, Lindvall O, Kokaia Z. Anterograde delivery of brain-derived neurotrophic factor to striatum via nigral transduction of recombinant adeno-associated virus increases neuronal death but promotes neurogenic response following stroke. The European Journal of Neuroscience. 17: 2667-78. PMID 12823474 DOI: 10.1046/J.1460-9568.2003.02713.X |
0.572 |
|
| 2003 |
Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Björklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America. 100: 2884-9. PMID 12601150 DOI: 10.1073/Pnas.0536383100 |
0.434 |
|
| 2003 |
Rosenblad C, Georgievska B, Kirik D. Long-term striatal overexpression of GDNF selectively downregulates tyrosine hydroxylase in the intact nigrostriatal dopamine system. The European Journal of Neuroscience. 17: 260-70. PMID 12542662 DOI: 10.1046/J.1460-9568.2003.02456.X |
0.506 |
|
| 2002 |
Georgievska B, Kirik D, Björklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Experimental Neurology. 177: 461-74. PMID 12429192 DOI: 10.1006/Exnr.2002.8006 |
0.511 |
|
| 2002 |
Arvidsson A, Collin T, Kirik D, Kokaia Z, Lindvall O. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nature Medicine. 8: 963-70. PMID 12161747 DOI: 10.1038/Nm747 |
0.547 |
|
| 2002 |
Winkler C, Kirik D, Björklund A, Cenci MA. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiology of Disease. 10: 165-86. PMID 12127155 DOI: 10.1006/Nbdi.2002.0499 |
0.598 |
|
| 2002 |
Georgievska B, Kirik D, Rosenblad C, Lundberg C, Björklund A. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport. 13: 75-82. PMID 11924898 DOI: 10.1097/00001756-200201210-00019 |
0.667 |
|
| 2002 |
Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 22: 2780-91. PMID 11923443 DOI: 10.1523/Jneurosci.22-07-02780.2002 |
0.703 |
|
| 2002 |
Kirik D, Georgievska B, Burger C, Winkler C, Muzyczka N, Mandel RJ, Bjorklund A. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proceedings of the National Academy of Sciences of the United States of America. 99: 4708-13. PMID 11917105 DOI: 10.1073/Pnas.062047599 |
0.628 |
|
| 2002 |
Lundblad M, Andersson M, Winkler C, Kirik D, Wierup N, Cenci MA. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. The European Journal of Neuroscience. 15: 120-32. PMID 11860512 DOI: 10.1046/J.0953-816X.2001.01843.X |
0.571 |
|
| 2001 |
Kirik D, Georgievska B, Rosenblad C, Björklund A. Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. The European Journal of Neuroscience. 13: 1589-99. PMID 11328352 DOI: 10.1046/J.0953-816X.2001.01534.X |
0.472 |
|
| 2001 |
Kirik D, Winkler C, Björklund A. Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 2889-96. PMID 11306640 DOI: 10.1523/Jneurosci.21-08-02889.2001 |
0.629 |
|
| 2000 |
Winkler C, Kirik D, Björklund A, Dunnett SB. Transplantation in the rat model of Parkinson's disease: ectopic versus homotopic graft placement. Progress in Brain Research. 127: 233-65. PMID 11142030 DOI: 10.1016/S0079-6123(00)27012-X |
0.706 |
|
| 2000 |
Björklund A, Kirik D, Rosenblad C, Georgievska B, Lundberg C, Mandel RJ. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Research. 886: 82-98. PMID 11119690 DOI: 10.1016/S0006-8993(00)02915-2 |
0.717 |
|
| 2000 |
Kirik D, Rosenblad C, Björklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. The European Journal of Neuroscience. 12: 3871-82. PMID 11069582 DOI: 10.1046/J.1460-9568.2000.00274.X |
0.456 |
|
| 2000 |
Fricker-Gates RA, Winkler C, Kirik D, Rosenblad C, Carpenter MK, Björklund A. EGF infusion stimulates the proliferation and migration of embryonic progenitor cells transplanted in the adult rat striatum. Experimental Neurology. 165: 237-47. PMID 10993684 DOI: 10.1006/Exnr.2000.7482 |
0.522 |
|
| 2000 |
Kirik D, Rosenblad C, Bjorklund A, Mandel RJ. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 4686-700. PMID 10844038 DOI: 10.1523/Jneurosci.20-12-04686.2000 |
0.526 |
|
| 2000 |
Rosenblad C, Kirik D, Björklund A. Sequential administration of GDNF into the substantia nigra and striatum promotes dopamine neuron survival and axonal sprouting but not striatal reinnervation or functional recovery in the partial 6-OHDA lesion model. Experimental Neurology. 161: 503-16. PMID 10686072 DOI: 10.1006/Exnr.1999.7296 |
0.454 |
|
| 2000 |
Rosenblad C, Grønborg M, Hansen C, Blom N, Meyer M, Johansen J, Dagø L, Kirik D, Patel UA, Lundberg C, Trono D, Björklund A, Johansen TE. In vivo protection of nigral dopamine neurons by lentiviral gene transfer of the novel GDNF-family member neublastin/artemin. Molecular and Cellular Neurosciences. 15: 199-214. PMID 10673327 DOI: 10.1006/Mcne.1999.0817 |
0.668 |
|
| 1999 |
Rosenblad C, Kirik D, Björklund A. Neurturin enhances the survival of intrastriatal fetal dopaminergic transplants. Neuroreport. 10: 1783-7. PMID 10501575 DOI: 10.1097/00001756-199906030-00029 |
0.475 |
|
| 1999 |
Rosenblad C, Kirik D, Devaux B, Moffat B, Phillips HS, Björklund A. Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinson's disease after administration into the striatum or the lateral ventricle. The European Journal of Neuroscience. 11: 1554-66. PMID 10215908 DOI: 10.1046/J.1460-9568.1999.00566.X |
0.464 |
|
| 1998 |
Kirik D, Rosenblad C, Björklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Experimental Neurology. 152: 259-77. PMID 9710526 DOI: 10.1006/Exnr.1998.6848 |
0.418 |
|
| 1998 |
Horger BA, Nishimura MC, Armanini MP, Wang LC, Poulsen KT, Rosenblad C, Kirik D, Moffat B, Simmons L, Johnson E, Milbrandt J, Rosenthal A, Bjorklund A, Vandlen RA, Hynes MA, et al. Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 18: 4929-37. PMID 9634558 DOI: 10.1523/Jneurosci.18-13-04929.1998 |
0.464 |
|
| 1997 |
Björklund A, Rosenblad C, Winkler C, Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiology of Disease. 4: 186-200. PMID 9361295 DOI: 10.1006/Nbdi.1997.0151 |
0.635 |
|
| Show low-probability matches. |